SARS-CoV-2 interfaces furthermore with the renin-angiotensin-aldosterone system (RAAS) through ACE2 and there are concerns that RAAS inhibitors may change ACE2 expression and thus COVID-19 virulence. This evidence concerns the gene ACE2 and COVID-19.